스마트 생검 기기 시장 : 기술 유형, 구성부품, 시술 유형, 자동화 레벨, 용도, 최종 사용자별 예측(2026-2032년)

The Smart Biopsy Devices Market is projected to grow by USD 9.11 billion at a CAGR of 6.53% by 2032.

Smart Biopsy Devices Executive Summary

Smart biopsy devices are becoming central to precision oncology as health systems work to diagnose cancer earlier, reduce repeat procedures, and obtain higher-quality tissue for molecular testing. The clinical need is substantial: the International Agency for Research on Cancer reported nearly 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, reinforcing the importance of accurate, minimally invasive tissue acquisition.

The market spans image-guided biopsy systems, vacuum-assisted biopsy devices, robotic and navigation-enabled platforms, smart needles, integrated sensing tools, and software that supports targeting, sampling confirmation, workflow documentation, and pathology coordination. Demand is strongest where screening programs, interventional radiology capacity, and tumor profiling are expanding together, particularly as tissue adequacy becomes essential for next-generation sequencing, immunohistochemistry, and companion diagnostic selection.

Transformative Shifts in the Smart Biopsy Landscape

The smart biopsy devices landscape is shifting from procedure-specific hardware toward connected, data-enabled diagnostic ecosystems. Hospitals and specialty centers increasingly prioritize devices that improve targeting under ultrasound, CT, MRI, mammography, or endoscopic guidance while also supporting traceability, safety, and specimen adequacy.

Another major shift is the growing link between biopsy quality and downstream oncology decisions. As next-generation sequencing, immunohistochemistry, and companion diagnostics become routine in lung, breast, prostate, liver, and gastrointestinal cancers, providers need biopsy platforms that preserve tissue integrity and reduce insufficient samples. The World Health Organization's emphasis on early cancer detection further supports the adoption of minimally invasive biopsy technologies that can shorten diagnostic pathways and improve referral efficiency.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across the biopsy pathway rather than replacing clinicians at a single point. AI-enabled imaging can help identify suspicious lesions, support needle-path planning, improve segmentation, and standardize documentation; the U.S. FDA's public catalog of AI/ML-enabled medical devices now includes hundreds of cleared tools, demonstrating regulatory momentum for clinical AI.

In smart biopsy devices, the strongest near-term value is decision support. AI can reduce variability in lesion localization, improve workflow efficiency, and connect imaging findings with pathology and molecular data. Adoption remains dependent on validation, cybersecurity, explainability, bias assessment, clinical governance, and integration with radiology, oncology, pathology, and hospital information systems.

Key Regional Insights: Global Adoption Patterns

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in cancer screening, tertiary hospitals, digital health infrastructure, and advanced imaging capacity. The region's adoption is supported by rising cancer incidence, broader access to CT, MRI, ultrasound, and mammography, and policy efforts to strengthen early diagnosis. North America remains a high-adoption region because of established interventional radiology networks, reimbursement pathways, FDA oversight, cancer screening utilization, and strong demand for minimally invasive cancer diagnostics that support precision medicine.

Europe benefits from organized screening programs, medical device regulation under EU MDR, and broad use of image-guided biopsy in oncology pathways, with growing emphasis on clinical evidence, post-market surveillance, and interoperability. Latin America is advancing through private hospital investment, public cancer-control programs, and rising cancer awareness, while the Middle East is supported by specialty hospital growth, national health transformation strategies, and oncology center development in Gulf economies. Africa remains underpenetrated, with opportunities tied to pathology access, imaging availability, workforce training, specimen transport systems, and affordable device and service models suited to resource-variable settings.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is shaped by expanding private healthcare, urban diagnostic centers, and government cancer-control initiatives, particularly in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where access to advanced imaging and oncology referral networks is improving. GCC countries are adopting advanced biopsy platforms through national health transformation programs, oncology centers of excellence, medical tourism strategies, and investments in digital hospitals that support integrated imaging and pathology workflows.

The European Union is driven by harmonized quality standards, screening infrastructure, cross-border regulatory expectations, and EU MDR compliance requirements that favor robust clinical evidence and post-market monitoring. BRICS markets combine large cancer burdens with uneven access to imaging, pathology, and specialist care, creating scale opportunities for cost-effective smart biopsy systems that improve sample adequacy and reduce repeat procedures. G7 countries lead in premium adoption, AI validation, molecular oncology integration, and evidence-based procurement, while NATO member markets benefit from strong hospital procurement systems, established medtech distribution, cybersecurity expectations, and resilient healthcare infrastructure planning.

Key Country Insights: Priority Markets for Smart Biopsy Devices

The United States leads commercial adoption through high cancer screening volumes, specialty imaging centers, FDA-cleared device pathways, and broad use of molecular diagnostics, while Canada emphasizes quality, safety, and equitable access across provincial health systems. Mexico and Brazil are growing as private networks, public cancer programs, and diagnostic imaging investments expand capacity for breast, lung, prostate, liver, and gastrointestinal cancer workups.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong demand for image-guided biopsy due to organized screening, multidisciplinary oncology care, and established interventional radiology services, while Russia's market is influenced by domestic procurement policies, regional hospital capacity, and access to advanced imaging. China and India offer major volume potential as oncology infrastructure expands, cancer awareness rises, and precision medicine adoption increases; Japan, Australia, and South Korea are advanced markets where precision diagnostics, robotics, AI-supported imaging, high-quality radiology services, and structured cancer care pathways are gaining clinical relevance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated differentiation: improved targeting accuracy, fewer non-diagnostic samples, shorter procedure times, lower complication risk, and compatibility with molecular testing. Evidence generation should include multicenter studies, real-world workflow data, usability assessments, specimen adequacy outcomes, and health-economic endpoints that appeal to hospitals, payers, and oncology networks.

Commercial strategies should align devices with imaging platforms, pathology workflows, electronic health records, and AI-enabled reporting. Vendors should localize pricing and service models for emerging markets, invest in physician and technologist training, strengthen cybersecurity and interoperability, and prepare regulatory files that address software updates, human factors, risk management, clinical performance, and post-market surveillance.

Research Methodology

This executive summary is developed using secondary research from verified public sources, including international cancer statistics, regulatory agency databases, clinical guidelines, peer-reviewed literature, product documentation, hospital procurement trends, healthcare policy references, and public health program materials.

Insights are triangulated across demand indicators, technology adoption signals, regional healthcare infrastructure, reimbursement context, clinical practice standards, and regulatory developments. The analysis emphasizes data-backed interpretation and excludes unsupported market-size, market-share, and market-forecast claims where verified public figures are not available.

Conclusion: Smart Biopsy Devices Outlook

Smart biopsy devices are evolving from mechanical sampling tools into intelligent diagnostic platforms that connect imaging, navigation, tissue acquisition, pathology, and oncology decision-making. This evolution is being accelerated by rising cancer incidence, precision medicine, AI-enabled imaging, and the need for faster, safer, and more reliable diagnosis.

Organizations that combine clinical evidence, AI readiness, workflow integration, regulatory discipline, training support, and region-specific commercialization will be best positioned. The long-term opportunity lies in helping providers obtain the right tissue, from the right target, at the right time, with confidence, efficiency, and clear value for patient care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Smart Biopsy Devices Market, by Technology Type

• 7.1. Imaging Integrated Smart Biopsy
  • 7.1.1. Ultrasound Integrated Systems
  • 7.1.2. MRI Integrated Systems
  • 7.1.3. CT Integrated Systems
• 7.2. Optical Biopsy Technologies
  • 7.2.1. Fluorescence Based Biopsy
  • 7.2.2. Spectroscopy Based Biopsy
• 7.3. AI Driven Biopsy Systems

8. Smart Biopsy Devices Market, by Component

• 8.1. Accessories
  • 8.1.1. Cannulas
  • 8.1.2. Coaxial Systems
  • 8.1.3. Markers & Clips
• 8.2. Localization Devices
• 8.3. Procedure Kits & Trays
• 8.4. Needle-Based Biopsy Instruments

9. Smart Biopsy Devices Market, by Procedure Type

• 9.1. Minimally Invasive Biopsy
• 9.2. Surgical Biopsy

10. Smart Biopsy Devices Market, by Automation Level

• 10.1. Manual Systems
• 10.2. Semi Automated Systems
• 10.3. Fully Automated Systems

11. Smart Biopsy Devices Market, by Application

• 11.1. Breast Cancer
• 11.2. Liver Cancer
• 11.3. Lung Cancer
• 11.4. Prostate Cancer
• 11.5. Skin Cancer
  • 11.5.1. Melanoma Diagnosis
  • 11.5.2. Non Melanoma Diagnosis
• 11.6. Gastrointestinal Cancer
  • 11.6.1. Esophageal
  • 11.6.2. Gastric
  • 11.6.3. Colorectal
• 11.7. Kidney Cancer

12. Smart Biopsy Devices Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Clinics
• 12.3. Diagnostic Centers
• 12.4. Hospitals

13. Smart Biopsy Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Smart Biopsy Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Smart Biopsy Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Advin Health Care
• 17.2. Argon Medical Devices, Inc.
• 17.3. B. Braun SE
• 17.4. Becton, Dickinson and Company
• 17.5. Boston Scientific Corporation
• 17.6. Cardinal Health, Inc.
• 17.7. ConMed Corporation
• 17.8. Cook Group Incorporated
• 17.9. Danaher Corporation
• 17.10. Dr. Japan Co., Ltd.
• 17.11. Fujifilm Holdings Corp.
• 17.12. Hologic, Inc.
• 17.13. INRAD, Inc.
• 17.14. IZI Medical Products
• 17.15. Johnson & Johnson Services, Inc.
• 17.16. Medtronic plc
• 17.17. Merit Medical Systems, Inc.
• 17.18. MicroPort Scientific Corporation
• 17.19. Olympus Corporation
• 17.20. Planmed Oy
• 17.21. Stryker Corporation
• 17.22. Summit Medical LLC
• 17.23. Teleflex Incorporated
• 17.24. TransMed7, LLC
• 17.25. Trivitron Healthcare